NVP-AEW541

NVP-AEW541

Biochem/physiol Actions

NVP-AEW541 is a reversible, ATP-competitive, orally available insulin-like growth factor-I receptor (IGF-IR, IGF-1R) inhibitor that, despite its equipotency against recombinant kinase domains of insulin receptor (InsR) and IGF-IR in cell-free kinase assays (IC50 = 140 & 150 nM, respectively), exhibits high selectivity toward cellular autophosphorylation of endogenous full-length IGF-1R (IC50 = 86 nM) over InsR (IC50 = 2.3 µM), HER1, PDGFR, c-Kit, and Bcr-Abl p210 (IC50 >5 µM). AEW541 effectively inhibits IGF-IR-mediated signaling and cancer survival (IC50 = 105 nM/MCF-7 soft agar growth, 1.64 µM/NWT-21 proliferation) in cultures and tumor growth in vivo (20 to 50 mg/kg twice daily p.o.; NWT-21 fibrosarcoma & TC-71 musculoskeletal sarcoma xenografts in mice).

No detailed specifications are available for this product.

There are no downloads for this product.

Code Description Colour Manufacturer Storage Temp. Solubility Form Assay Price Quantity
3575643 NVP-AEW541 white to beige SIGMA-ALDRICH 2-8°C DMSO: 2 mg/mL, clear powder ≥98% (HPLC)
£831.54 (exc VAT) per 25MG
-
+
3575644 NVP-AEW541 white to beige SIGMA-ALDRICH 2-8°C DMSO: 2 mg/mL, clear powder ≥98% (HPLC)
£242.36 (exc VAT) per 5MG
-
+